Noninvasive detection of silent coronary artery disease in patients with essential hypertension, alone or associated with type 2 diabetes mellitus, using dipyridamole stress 99mtechnetium sestamibi myocardial perfusion imaging

Canadian Journal of Cardiology

Volumn 22, Issue SUPPL. A, 2006, Pages

  Lacourcière, Yves ^a   Côte, Christian ^a   Lefebvre, Jean ^a   Dumont, Marcel ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Diabetes type 2; Dipyridamole stress 99mtechetium sestamibi SPECT imaging; Hypertension; Silent CAD

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPYRIDAMOLE; GLYCERYL TRINITRATE; INSULIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; ORAL ANTIDIABETIC AGENT; PHOSPHODIESTERASE V INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSPNEA; EARLY DIAGNOSIS; ESSENTIAL HYPERTENSION; EXERCISE TEST; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; PRACTICE GUIDELINE; PREVALENCE; PROSPECTIVE STUDY; PROTEINURIA; RISK ASSESSMENT; SCORING SYSTEM; SILENT MYOCARDIAL ISCHEMIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; DIABETES MELLITUS, TYPE 2; DIPYRIDAMOLE; EXERCISE TEST; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33845711762     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Frohlich ED, Apstein C, Chobanian AV, et al. The heart in hypertension. N Engl J Med 1992;327:998-1008. (Erratum in 1992;327:1768).
2. Young LH, Chyun PA. Heart disease in patients with diabetes. In: Porte DJ, Sherwin RS, Baron A, eds. Ellenberg and Rifkin's Diabetes Mellitus: Theory and Practice, 6th edn. New York: McGraw-Hill, 2002:823-44.
3. Hachamovitch R, Berman DS, Kiat H, et al. Exercise myocardial perfusion SPECT in patients without known coronary artery disease: Incremental prognostic value and use in risk stratification. Circulation 1996;93:905-14.
4. Nesto RW, Phillips RT. Asymptomatic myocardial ischemia in diabetic patients. Am J Med 1986;80:40-7.
5. De Lorenzo A, Lima RS, Siqueira-Filho AG, Pantoja MR. Prevalence and prognostic value of perfusion defects detected by stress technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography in asymptomatic patients with diabetes mellitus and no known coronary artery disease. Am J Cardiol 2002;90:827-32.
6. Zellweger MJ, Hachamovitch R, Kang X, et al. Prognostic relevance of symptoms versus objective evidence of coronary artery disease in diabetic patients. Eur Heart J 2004;25:543-50.
7. Boon D, Piek JJ, van Montfrans GA. Silent ischaemia and hypertension. J Hypertens 2000;18:1355-64.
8. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10-11 February 1998, Miami, Florida. American Diabetes Association. Diabetes Care 1998;21:1551-9.
9. American Society of Nuclear Cardiology. Updated imaging guidelines for nuclear cardiology procedures, part 1. J Nucl Cardiol 2001;8:G1-G58.
10. Berman DS, Hachamovitch R, Kiat H, et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: A basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol 1995;26:639-47.
11. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging - Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation 2003;108:1404-18.
12. Beller GA, Bergmann SR. Myocardial perfusion imaging agents: SPECT and PET. J Nucl Cardiol 2004;11:71-86.
13. Gremillet E, Champailler A. Comparative myocardial uptake of technetium-99m sestamibi and technetium-99m tetrofosmin one hour after stress injection. Eur J Nucl Med 1998;25:1502-10.
14. Soman P, Taillefer R, DePuey EG, Udelson JE, Lahiri A. Enhanced detection of reversible perfusion defects by TC-99m sestamibi compared to TC-99m tetrofosmin during vasodilator stress SPECT imaging in mild-to-moderate coronary artery disease. J Am Coll Cardiol 2001;37:458-62.
15. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Am J Cardiol 1997;79:134-9.
16. Wackers FJ, Young LH, Inzucchi SE, et al; Detection of Ischemia in Asymptomatic Diabetics Investigators. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: The DIAD study. Diabetes Care 2004;27:1954-61. (Erratum in 2005;28:504).
17. Elhendy A, van Domburg RT, Bax JJ, Ibrahim MM, Roelandt JR. Myocardial perfusion abnormalities in treated hypertensive patients without known coronary artery disease. J Hypertens 1999;17:1601-6.
18. Rutter MK, McComb JM, Brady S, Marshall SM. Silent myocardial ischemia and microalbuminuria in asymptomatic subjects with non-insulin-dependent diabetes mellitus. Am J Cardiol 1999;83:27-31.
19. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients undergoing stress myocardial perfusion single-photon emission computed tomography. Circulation 2003;107:2900-7.
20. Mooradian AD. Cardiovascular disease in type 2 diabetes mellitus: Current Management Guidelines. Arch Intern Med 2003;163:33-40.
21. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Stress myocardial perfusion single-photon emission computed tomography is clinically effective and cost-effective in risk stratification of patients with a high likelihood of coronary artery disease (CAD) but no known CAD. J Am Coll Cardiol 2004;43:200-8.
22. Underwood SR, Anagnostopoulos C, Cerqueira M, et al. Myocardial perfusion scintigraphy. Eur J Nucl Med Mol Imaging 2004;31:261-91.
23. Berman DS, Kiat H, Friedman JD, Diamond G. Clinical applications of exercise nuclear cardiology studies in the era of healthcare reform. Am J Cardiol 1995;75:3D-13D.
24. Blumenthal RS, Cohn G, Schulman SP. Medical therapy versus coronary angioplasty in stable coronary artery disease: A critical review of the literature. J Am Coll Cardiol 2000;36:668-73.
25. Sobel BE, Frye R, Detre KM; Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: Rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 2003;107:636-42. (Erratum in 2003;108:500).